Lietuva - lietuvių - Ecolab

ecolab deutschland gmbh -

Lietuva - lietuvių - Ecolab

ecolab deutschland gmbh -

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazolas - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics sisteminiam vartojimui - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ir 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 ir 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ir 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invazinių aspergillosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b arba itraconazole, arba pacientams, kurie netoleruoja tokių vaistų;- fusariosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b, arba pacientams, kurie netoleruoja amphotericin b;- chromoblastomycosis ir mycetoma pacientams, sergantiems liga, kuri yra ugniai atsparios į itraconazole, arba pacientams, kurie netoleruoja itraconazole;- coccidioidomycosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b, itraconazole ar fluconazole, arba pacientams, kurie netoleruoja tokių vaistų;- burnos ir ryklės kandidozė: kaip pirmos eilės gydymas pacientams, kurie serga sunkia liga ar yra imuninės sistemos sutrikimų, į kuriuos atsako į aktualius terapija, tikimasi, bus prastas. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

l. r. tamulio firma „meditalika“, radvilų dvaro g. 4, lt-48320 kaunas. - natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris - veikliosios medžiagos cas nr.: 2893-78-9, eb nr.: 220-767-7, veikliosios medžiagos pavadinimas: natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris, koncentracija: 34% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

l. r. tamulio firma „meditalika“, radvilų dvaro g. 4, lt-48320 kaunas. - natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris - veikliosios medžiagos cas nr.: 2893-78-9, eb nr.: 220-767-7, veikliosios medžiagos pavadinimas: natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris, koncentracija: 29% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

kay bvba, havenlaan 4, be-3980 tessenderlo (belgija). - natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris - veikliosios medžiagos cas nr.: 2893-78-9, eb nr.: 220-767-7, veikliosios medžiagos pavadinimas: natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris, koncentracija: 50% , veiklioji - geriamasis vanduo

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

kay bvba, havenlaan 4, be-3980 tessenderlo, belgija. - natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris - veikliosios medžiagos cas nr.: 2893-78-9, eb nr.: 220-767-7, veikliosios medžiagos pavadinimas: natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris, koncentracija: 50% , veiklioji - geriamasis vanduo

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

kay n.v., havenlaan 4, be-3980 tessenderlo (belgija). - natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris - veikliosios medžiagos cas nr.: 2893-78-9, eb nr.: 220-767-7, veikliosios medžiagos pavadinimas: natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris, koncentracija: 50% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

kay n.v., havenlaan 4, be-3980 tessenderlo (belgija). - natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris - veikliosios medžiagos cas nr.: 2893-78-9, eb nr.: 220-767-7, veikliosios medžiagos pavadinimas: natrio-3,5-dichloro-s-triazino-2,4,6-trionas; natrio dichlorizocianuratas; troklozennatris, koncentracija: 50% , veiklioji - maisto ir pašarų sritis

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

delaval nv, industriepark – drongen 10, 9031 gent, belgija - natrio dichlorizocianurato dihidratas - veikliosios medžiagos cas nr.: 51580-86-0, eb nr.: 220-767-7, veikliosios medžiagos pavadinimas: natrio dichlorizocianurato dihidratas, koncentracija: 100% , veiklioji - maisto ir pašarų sritis